$QURE
uniQure N.V.

2022 Q4 Form 10-Q Financial Statement

#000155837022015906 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $102.7M $1.449M
YoY Change 78.1% -27.15%
Cost Of Revenue $1.650M $861.0K
YoY Change -8.23%
Gross Profit $101.1M $588.0K
YoY Change 80.87% -70.44%
Gross Profit Margin 98.39% 40.58%
Selling, General & Admin $18.26M $13.32M
YoY Change 30.72% 10.82%
% of Gross Profit 18.06% 2265.99%
Research & Development $58.76M $48.07M
YoY Change 38.78% 31.94%
% of Gross Profit 58.12% 8174.83%
Depreciation & Amortization $2.331M $2.103M
YoY Change 25.86% 18.15%
% of Gross Profit 2.31% 357.65%
Operating Expenses $74.59M $61.39M
YoY Change 38.59% 26.7%
Operating Profit $26.50M -$59.52M
YoY Change 1181.48% 32.26%
Interest Expense -$22.03M $3.069M
YoY Change -469.75% 59.51%
% of Operating Profit -83.11%
Other Income/Expense, Net $2.125M $199.0K
YoY Change -1428.13% -7.01%
Pretax Income $6.600M -$48.19M
YoY Change -16.08% 32.23%
Income Tax -$207.0K -$329.0K
% Of Pretax Income -3.14%
Net Earnings $6.807M -$47.86M
YoY Change -17.07% 31.0%
Net Earnings / Revenue 6.63% -3302.76%
Basic Earnings Per Share -$1.02
Diluted Earnings Per Share $0.15 -$1.02
COMMON SHARES
Basic Shares Outstanding 46.82M 46.73M
Diluted Shares Outstanding 46.77M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $352.8M $440.3M
YoY Change -36.57% -23.88%
Cash & Equivalents $228.0M $440.3M
Short-Term Investments $124.8M
Other Short-Term Assets $14.63M $16.59M
YoY Change 10.72% 43.86%
Inventory $6.924M $4.075M
Prepaid Expenses $11.82M $13.69M
Receivables $102.4M $3.603M
Other Receivables $0.00 $0.00
Total Short-Term Assets $476.8M $464.6M
YoY Change -24.11% -21.76%
LONG-TERM ASSETS
Property, Plant & Equipment $50.53M $47.89M
YoY Change 16.15% 16.19%
Goodwill $25.58M $23.42M
YoY Change -7.43% -16.54%
Intangibles $58.78M
YoY Change -6.23%
Long-Term Investments $39.98M
YoY Change
Other Assets $6.061M $6.085M
YoY Change 2.78% 7.36%
Total Long-Term Assets $228.2M $173.7M
YoY Change 26.11% -3.98%
TOTAL ASSETS
Total Short-Term Assets $476.8M $464.6M
Total Long-Term Assets $228.2M $173.7M
Total Assets $705.0M $638.2M
YoY Change -12.88% -17.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.98M $7.566M
YoY Change 339.01% 40.82%
Accrued Expenses $30.57M $26.44M
YoY Change 7.32% -14.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $75.92M $63.97M
YoY Change 106.51% 52.62%
LONG-TERM LIABILITIES
Long-Term Debt $102.8M $102.4M
YoY Change 1.81% 43.23%
Other Long-Term Liabilities $935.0K $3.053M
YoY Change -77.93% -19.83%
Total Long-Term Liabilities $153.0M $153.1M
YoY Change -13.36% 7.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $75.92M $63.97M
Total Long-Term Liabilities $153.0M $153.1M
Total Liabilities $229.0M $217.1M
YoY Change 7.29% 18.05%
SHAREHOLDERS EQUITY
Retained Earnings -$581.9M -$588.7M
YoY Change 27.86% 27.06%
Common Stock $2.838M $2.830M
YoY Change 1.28% 1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $476.0M $421.2M
YoY Change
Total Liabilities & Shareholders Equity $705.0M $638.2M
YoY Change -12.88% -17.61%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $6.807M -$47.86M
YoY Change -17.07% 31.0%
Depreciation, Depletion And Amortization $2.331M $2.103M
YoY Change 25.86% 18.15%
Cash From Operating Activities -$54.68M -$48.99M
YoY Change 16.12% 22.0%
INVESTING ACTIVITIES
Capital Expenditures $5.066M -$3.985M
YoY Change -242.58% -48.21%
Acquisitions
YoY Change
Other Investing Activities -$163.1M -$1.078M
YoY Change -97.84%
Cash From Investing Activities -$168.2M -$5.063M
YoY Change 4634.37% -91.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 601.0K 301.0K
YoY Change -97.99% -283.54%
NET CHANGE
Cash From Operating Activities -54.68M -48.99M
Cash From Investing Activities -168.2M -5.063M
Cash From Financing Activities 601.0K 301.0K
Net Change In Cash -222.3M -53.75M
YoY Change 971.33% -45.13%
FREE CASH FLOW
Cash From Operating Activities -$54.68M -$48.99M
Capital Expenditures $5.066M -$3.985M
Free Cash Flow -$59.75M -$45.01M
YoY Change 37.23% 38.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46815109
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46298635
dei Entity Central Index Key
EntityCentralIndexKey
0001590560
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36294
dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
dei Entity Address Country
EntityAddressCountry
NL
dei City Area Code
CityAreaCode
31
dei Local Phone Number
LocalPhoneNumber
20-240-6000
dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
us-gaap Share Based Compensation
ShareBasedCompensation
22290000
dei Trading Symbol
TradingSymbol
QURE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46815109
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
440313000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
556256000
CY2022Q3 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
3603000
CY2021Q4 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
58768000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4075000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13692000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10540000
CY2022Q3 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2894000
CY2021Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2675000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
464577000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
628239000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40500000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36900000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47886000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43505000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27804000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25573000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53837000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
62686000
CY2022Q3 us-gaap Goodwill
Goodwill
23418000
CY2021Q4 us-gaap Goodwill
Goodwill
27633000
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
14627000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15647000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6085000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5897000
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
173657000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
180941000
CY2022Q3 us-gaap Assets
Assets
638234000
CY2021Q4 us-gaap Assets
Assets
809180000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7566000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2502000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26437000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
23537000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6434000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5774000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
63974000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36763000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
102394000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100963000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29893000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28987000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9158000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29542000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
8592000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12913000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3053000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4236000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
153090000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
176641000
CY2022Q3 us-gaap Liabilities
Liabilities
217064000
CY2021Q4 us-gaap Liabilities
Liabilities
213404000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46815109
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46298635
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2830000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2802000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1100078000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1076972000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-93000000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28856000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-588738000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455142000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
421170000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
638234000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
809180000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1449000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1989000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3738000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
466311000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
CY2022Q3 us-gaap Manufacturing Costs
ManufacturingCosts
861000
us-gaap Manufacturing Costs
ManufacturingCosts
1693000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48068000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36432000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139263000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101209000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13324000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12023000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36802000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42323000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
62253000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
48455000
us-gaap Costs And Expenses
CostsAndExpenses
177758000
us-gaap Costs And Expenses
CostsAndExpenses
166710000
CY2022Q3 us-gaap Other Income
OtherIncome
1485000
CY2021Q3 us-gaap Other Income
OtherIncome
1680000
us-gaap Other Income
OtherIncome
4981000
us-gaap Other Income
OtherIncome
9622000
CY2022Q3 us-gaap Other Expenses
OtherExpenses
199000
CY2021Q3 us-gaap Other Expenses
OtherExpenses
214000
us-gaap Other Expenses
OtherExpenses
621000
us-gaap Other Expenses
OtherExpenses
673000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-59518000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-169660000
us-gaap Operating Income Loss
OperatingIncomeLoss
308550000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
us-gaap Investment Income Interest
InvestmentIncomeInterest
117000
us-gaap Investment Income Interest
InvestmentIncomeInterest
123000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3069000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1924000
us-gaap Interest Expense
InterestExpense
8279000
us-gaap Interest Expense
InterestExpense
5377000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
14362000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10436000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42328000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
21645000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48186000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36442000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-134859000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
324941000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-329000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1263000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3560000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47857000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-133596000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-25370000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13288000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-64144000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-27790000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73227000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49819000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-197740000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
293591000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13288000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
914000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.87
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46772430
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46152404
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46680667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45888769
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46772430
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46152404
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46680667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46780963
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5955000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
97000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
590755000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
486488000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47857000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-25370000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
260000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7608000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
41000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
421170000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27790000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29565000
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1824000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18747000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
146000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
590755000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-133596000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-64144000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
713000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22290000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
131000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
421170000
us-gaap Profit Loss
ProfitLoss
-133596000
us-gaap Profit Loss
ProfitLoss
321381000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6206000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5447000
us-gaap Share Based Compensation
ShareBasedCompensation
18747000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1263000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3560000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
6875000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
416000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
36390000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
23242000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
581000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2862000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
-41992000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
1993000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4075000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4529000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2003000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3633000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11592000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90380000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
335049000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12622000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13885000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1900000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
49949000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14522000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63834000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
844000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1971000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30899000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1334000
us-gaap Repayments Of Debt
RepaymentsOfDebt
1175000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
844000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64964000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11876000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2589000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-115934000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
333590000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
559353000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
443419000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
581270000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
440313000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
578464000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3106000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2806000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
443419000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
581270000
us-gaap Interest Paid Net
InterestPaidNet
6410000
us-gaap Interest Paid Net
InterestPaidNet
4503000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
1766000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
415000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47857000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-133596000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></span><span style="display:inline-block;width:18pt;"/><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
23500000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
32700000
CY2020Q4 qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47857000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1447000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2178000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
450000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4075000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
600000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-133596000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46772430
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46152404
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46680667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45888769
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46772430
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46152404
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46680667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46780963
CY2022Q3 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
13497000
CY2021Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
13012000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12940000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12603000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2872000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26437000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
700000
CY2021Q3 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P1Y
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P3Y
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6613528
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4200111
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6613528
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3309299

Files In Submission

Name View Source Status
0001558370-22-015906-index-headers.html Edgar Link pending
0001558370-22-015906-index.html Edgar Link pending
0001558370-22-015906.txt Edgar Link pending
0001558370-22-015906-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20220930.xsd Edgar Link pending
qure-20220930x10q.htm Edgar Link pending
qure-20220930xex31d1.htm Edgar Link pending
qure-20220930xex31d2.htm Edgar Link pending
qure-20220930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
qure-20220930_def.xml Edgar Link unprocessable
qure-20220930_lab.xml Edgar Link unprocessable
qure-20220930_pre.xml Edgar Link unprocessable
qure-20220930x10q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
qure-20220930_cal.xml Edgar Link unprocessable